Just received this from the BNF,
Dapagliflozin
Dapagliflozin, a new first-in-class antidiabetic drug, has been added to BNF section 6.1.2.3 for the treatment of type 2 diabetes. It reversibly inhibits sodium-glucose co-transporter 2 (SGLT2) in the renal proximal convoluted tubule to reduce...